Latest Breaking News On - Recent worsening heart - Page 1 : comparemela.com

Sotagliflozin May Steal the Spotlight in Heart Failure, but Questions Remain

Although newly approved, there is some debate regarding the benefits and populations in which sotagliflozin will be the most effective.

United statesLexicon pharmaceuticals incYork heart associationNew york heart associationAmerican collegeAmerican heart associationQuick factsInjury incidenceGlobal burdenDisease studyHeart failureAmerican heart association joint committeeClinical practiceLexicon pharmaceuticalsNat cardiovasc resRecent worsening heart

Deepak Bhatt, MD, MPH: Need for In-Hospital Initiation, Uptitration of GDMT in Acute Heart Failure

Deepak Bhatt, MD, MPH, discusses the need to improve in-hospital initiation and uptitration of guideline-directed medical therapy in heart failure.

Eli lillyEuropean society of cardiologyEuropean societyConfidence intervalEurj heartRecent worsening heartHeart failureGdmt in heart failureSglt2 inhibitor

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesMedstar washington hospital centerTyler gluckmanSlaven sikiricaWilliam weintraubRahul aggarwalCraig granowitzPreston masonExchange commissionLexicon pharmaceuticalsAmerican heart association scientific sessionsTechnology hallLexicon pharmaceuticals incProvidence heart institutePennsylvania convention center

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored

Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation

District of columbiaUnited statesMedstar washington hospital centerCraig granowitzTyler gluckmanAlina cocuzzaWilliam weintraubRahul aggarwalSlaven sikiricaPreston masonProvidence heart instituteTechnology hallLexicon pharmaceuticalsLexicon pharmaceuticals incDrug administrationPennsylvania convention center

Clinical Overview: Sotagliflozin (Inpefa) for Heart Failure

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

Lexicon pharmaceuticals incAmerican college of cardiologyAfrica studioSotagliflozin approved for broadAmerican collegeVasc disRecent worsening heartNew drugChronic kidneyLexicon pharmaceuticals